Research and publication ethics

  • HOME
  • Research and publication ethics

All of the manuscripts should be prepared in strict observation of research and publication ethics guidelines recommended by the Council of Science Editors (CSE, (, International Committee of Medical Journal Editors (ICMJE, (, World Association of Medical Editors (WAME, ( and the Korean Association of Medical Journal Editors (KAMJE, ( Journal of Bone Metabolism (JBM) will follow the guidelines by the Committee on Publication Ethics (COPE, ( for settlement of any misconduct. In case of suspected misconduct such as fabrication, falsification or duplication, each ethical issue is followed by recommended actions as advised by COPE guidelines and flowcharts. All reviewers have a responsibility to report to the Editor about any suspected issues with the manuscript. If the investigation proves scientific misconduct, publish a retraction of the article. If warranted, the authors should be invited to prepare the retraction, which should be submitted with an assignment of copyright statement that has been signed by all authors. If the paper has not been published then the Editor can always reject the paper. Instances of misconduct in the publication process will be shared with the editorial board of the JBM journal. The Editor may wish to impose sanctions, notify editors of other biomedical journals, and depending on the severity of the allegation, notify the author's institution. The JBM will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when the misconduct is founded.

Clinical Trials
(1) Registration of Clinical Trial Research
It is recommended that any research that deals with a clinical trial be registered with a primary national clinical trial registration site, such as, or other sites accredited by the WHO as listed at
(2) Data Sharing Policy
JBM accepts the ICMJE Recommendations for data sharing statement policy ( All manuscripts reporting clinical trial results should submit a data sharing statement following the ICMJE guidelines from 1 July 2018. JBM follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (
Statement of Informed Consent and Institutional Review Board Approval
Copies of written informed consent and institutional review board (IRB) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct. In addition, for studies conducted with human subjects, the method by which informed consent was obtained from the participants (i.e., verbal or written) also needs to be stated in the Methods section.
  • Ex 1) This study complies with the Declaration of Helsinki and was performed according to ethics committee approval.
  • Ex 2) This study had institutional review board approval, and the need to obtain informed patient consent was waived.
  • Ex 3) This study had institutional review board approval, and all patients provided written informed consent.
  • Ex 4) Written informed consent was obtained from all patients, and the study protocol was approved by the institutional committee on human research, ensuring that it conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
  • Ex 5) This study was conducted in accordance with the principles of the Declaration of Helsinki, and all patients provided written informed consent prior to enrollment.
  • Ex 6) Ethics approval and informed consent were obtained.
  • Ex 7) All animals were treated in accordance with the Guidelines for The Care and Use of Laboratory Animals as adopted by the OOO University. This study was approved by the institutional animal care and use committee of OOO.
Patient Photographic and Videographic Consent
Patients introduced in the manuscripts should be informed and aware that their photographs, videotapes, and other images (imaging records) will be released by the authors, and the authors should attach the Authorization and Release Form available at the JBM website ( or including each patient’s signature.
Statement of Human and Animal Rights
Clinical research studies must state that all work was carried out in compliance with Ethical Principles for Medical Research Involving Human Subjects outlined in the Helsinki Declaration in 1975 ( [last updated in July 2018]). Clinical studies that do not meet the Helsinki Declaration guidelines will not be considered for publication. Human subjects must not be identifiable. A patient’s name, initials, hospital number, date of birth, or other protected healthcare information must never be disclosed. Animal research studies must state that all work was conducted according to the National or Institutional Guide for the Care and Use of Laboratory Animals and the ethical treatment of all experimental animals must conform to the guidelines provided by the Institutional Animal Care and Use Committee (IACUC). A statement of IRB status and IACUC must be included in the Methods section.
Copyright and Licensing
(1) Copyright policy: Upon publication of the articles, all the copyrights are transferred to the Korean Society for Bone and Mineral Research. Articles are accepted on the understanding that no substantial part other than the abstract has been or will be published elsewhere. A copyright transfer form should be submitted to the editorial office by faxing a copy to +82-70-4156-2230, by regular mail, or by emailing the scanned copyright transfer form at the time of acceptance. It is identical to the Creative Commons Attribution Noncommercial License at (
(2) Licensing information: This is an open-access journal distributed under the terms of the Creative Commons Attribution Non-commercial license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purpose ( (
(3) Supporting Information: This journal was supported by the Korean Federation of Science and Technology Societies (KOFST) Grant funded by the Korean Government (MEST).
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data 2) drafting the article or revising it critically for important intellectual content and 3) final approval of the version to be published. 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these 1, 2, 3, and 4 conditions. In addition, an author should be accountable for the parts of the work he or she has done and should be able to identify which co-authors are responsible for specific other parts of the work. Authors should have confidence in the integrity of the contributions of their coauthors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged as contributors not be authors. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion 2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author( s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors on the paper. Copyright assignment must be completed by every author.
Originality and Duplicate Publication
Redundant publication is defined as “reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s)”. A manuscript that is potentially redundant includes the following characteristics: (1) at least one of the authors has contributed to both or all reports (if there are no common authors, plagiarism is more likely than redundant publication); (2) the subject or study populations are often the same or similar; (3) the methodology is typically identical or nearly so and (4) the results and their interpretation generally vary little, if at all.
When submitting a manuscript, authors should include a letter informing the editor of any potential overlap with other already published material or material being evaluated for publication and should also state how the manuscript submitted to JBM differs substantially from other materials. If all or part of your patient population was previously reported, this should be mentioned in the Methods, with citation of the appropriate reference(s).
The duplication will be checked through CrossCheck ( before submission. If duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed.
Secondary Publication
It is possible to republish manuscripts if the manuscripts satisfy the condition of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by ICMJE available from
ICMJE as follows:
  • • The authors have received approval from the editors of both journals (the editor concerned with the secondary publication must have access to the primary version).
  • • The priority for the primary publication is respected by a publication interval negotiated by editors of both journals and the authors.
  • • The paper for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient.
  • • The secondary version faithfully reflects the data and interpretations of the primary version.
  • • The secondary version informs readers, peers, and documenting agencies that the paper has been published in whole or in part elsewhere—for example, with a note that might read, "This article is based on a study first reported in the (journal title, with full reference)"—and the secondary version cites the primary reference.
  • • The title of the secondary publication should indicate that it is a secondary publication (complete or abridged republication or translation) of a primary publication. Of note, the United States National Library of Medicine (NLM) does not consider translations as "republications" and does not cite or index them when the original article was published in a journal that is indexed in MEDLINE.
Preprint Policy
A preprint is a full draft research paper that is shared publicly before it has been peer-reviewed. JBM allows authors to submit the preprint to the journal. It is not treated as duplicate submission or duplicate publication. A DOI to that document must be provided so that reviewers and editors can evaluate the preprinted information and compare it with the submitted manuscript. The manuscript is accepted for publication, no revisions should be posted on the preprint server until the final manuscript is published online by JBM, and any such revisions must not deviate from the final version of the manuscript published by JBM. If your manuscript is accepted, JBM will include this DOI with your published manuscript.

Journal of Bone

Print ISSN: 2287-6375
Online ISSN: 2287-7029


Browse all articles >

Editorial Office
#1001, Hyundai Kirim Officetel, 42 Seocho-daero 78-gil, Seocho-gu, Seoul 06626, Korea
Tel: +82-2-3473-2231    Fax: +82-70-4156-2230    E-mail:                

Copyright © 2024 by The Korean Society for Bone and Mineral Research.

Developed in M2PI

Close layer
prev next